Association of protein disulfide isomerase family A, member 4, and inflammation in people living with HIV

Copyright © 2022 The Author(s). Published by Elsevier Ltd.. All rights reserved..

OBJECTIVES: Protein disulfide isomerase (PDI) family members are specific endoplasmic reticulum proteins associated with inflammation, obesity, and cancer. In HIV infection, the role of PDI family A, member 4 (PDIA4), is unclear. This study aimed to clarify the association between plasma PDIA4 levels and inflammation in people living with HIV (PLWH).

METHODS: In this study, 287 PLWH and 74 healthy participants were enrolled. The plasma PDIA4 values, demographic data, laboratory data, and other inflammatory markers were recorded. The association between PDIA4 level and inflammatory extent was analyzed using logistic regression and Spearman rank-order correlations. Other results were analyzed using Student's t-test or chi-square test.

RESULTS: In PLWH, the PDIA4 levels were positively associated with the inflammatory markers, interleukin 6 (r = 0.209, p = 0.001), and tumor necrosis factor-α (r = 0.162, p = 0.01) levels, but not with high-sensitivity C-reactive protein levels. Moreover, the plasma PDIA4 level of PLWH decreased after anti-viral treatment (p = 0.0001).

CONCLUSION: Plasma PDIA4 levels are closely associated with inflammation in PLWH and have a positive correlation with the viral load during anti-viral therapy.

Medienart:

E-Artikel

Erscheinungsjahr:

2023

Erschienen:

2023

Enthalten in:

Zur Gesamtaufnahme - volume:126

Enthalten in:

International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases - 126(2023) vom: 15. Jan., Seite 79-86

Sprache:

Englisch

Beteiligte Personen:

Wang, Ning-Chi [VerfasserIn]
Chen, Hsuan-Wei [VerfasserIn]
Lin, Te-Yu [VerfasserIn]

Links:

Volltext

Themen:

EC 5.3.4.1
Human immunodeficiency virus
Inflammation
Journal Article
PDIA4 protein, human
Protein Disulfide-Isomerases
Protein disulfide isomerase family A, member 4
Tumor Necrosis Factor-alpha

Anmerkungen:

Date Completed 06.01.2023

Date Revised 06.01.2023

published: Print-Electronic

Citation Status MEDLINE

doi:

10.1016/j.ijid.2022.11.010

funding:

Förderinstitution / Projekttitel:

PPN (Katalog-ID):

NLM34889161X